ASH

Clinically focused coverage from the American Society of Hematology (ASH) Annual Meeting, highlighting key data across malignant and nonmalignant hematologic disorders.

General Hematology

View All

Advanced visualization of immune cells and cancerous cells related to multiple myeloma, highlighting emerging treatment strategies and expert insights.

General Hematology

02/19/2026

Expert Insight on Emerging Strategies in Multiple Myeloma

Mehndi Dandwani, MD

Blood sample in a test tube with laboratory report background, highlighting hematology and oncology research.

General Hematology

01/11/2026

Key Studies Shaping Hematology, Community Oncology at ASH 2025

Sawyer Bawek, DO

Enhanced medical research on hematology and oncology at ASH 2025 conference with clinical laboratory professionals.

General Hematology

01/07/2026

ASH 2025 Breakthroughs: Key Studies Shaping Hematology and Community Oncology

Sawyer Bawek, DO

Leukemia

View All

An image of Dr. Jorge Cortes presenting AML and CML highlights from ASH 2025, featuring Dr. Rahul Gosain and Dr. Rohit Gosain, with a professional background related to hematology and oncology researc.

Leukemia

03/04/2026

AML and CML Highlights From ASH 2025

Jorge Cortes, MDRahul Gosain, MD, MBARohit Gosain, MD

Azacitidine and venetoclax combination therapy for AML, showcasing practice-changing insights from ASH 2025 presented by Jayastu Senapati and Uma Borate.

Leukemia

01/16/2026

Azacitidine in AML: Key Takeaways From the PARADIGM Study

Jayastu Senapati, MBBSUma Borate, MBBS

Advanced AML treatment discussing FLT3 inhibitors, menin targeting, and triplet regimens with experts Abhishek Maiti, MD, and Jorge Cortes, MD, in a clinical oncology-focused presentation.

Leukemia

01/01/2026

Targeted Combinations Transform AML Care

Abhishek Maiti, MDJorge Cortes, MD

1. Expert oncologists discussing future trends in chronic myeloid leukemia (CML) therapy and insights from key clinical trials including ASC4, OPTIC, and ASXL1 for 2025.

Leukemia

12/31/2025

ASH 2025 CML Highlights: Asciminib, Ponatinib Optimization, and Treatment Sequencing

Sawyer Bawek, DOFadi Haddad, MD

Bispecific antibodies and CAR T-cell therapy for emerging data in TP53-mutated AML and MDS, featuring experts Mycal Casey, DO, and Abishek Maiti, MD, at OncUpdates conference.

Leukemia

12/24/2025

Reviewing ASH 2025 Data for ALL and TP53-Mutated AML or MDS

Abhishek Maiti, MDMycal Casey, DO

1. Expert oncologists discussing treatment options for cancer, emphasizing Venetoclax-based regimens, targeted agents, and rapid molecular profiling for personalized therapy.

Leukemia

12/23/2025

Improving Venetoclax and Other Targeted Therapies in AML

Zachary Braunstein, MDJayastu Senapati, MBBS

Leukemia

12/20/2025

Ibrutinib Updates in CLL From ASH 2025

Mahesh Swaminathan, MB, MSVanthana Bharthi, MD

1. Expert insights on frontline BTK inhibitors and triplet therapy for CLL at ASH 2025, featuring Mahesh Swaminathan and Bita Fakhri.

Leukemia

12/18/2025

Breaking Down ASH 2025 Data on Frontline Pirtobrutinib in CLL

Bita Fakhri, MD, MPHMahesh Swaminathan, MB, MS

Non-covalent BTKi efficacy post-covalent BTKi or BCL-2 therapies in cancer treatment, featuring experts Claudia Villa Celi, MD, and Daniel Ermann, MD, for oncology research updates.

Leukemia

12/18/2025

Sequencing BTKi Therapies in Patients With CLL

Claudia Villa Celi, MDDaniel Ermann, MD

1. Two healthcare professionals, a male and female doctor, smiling against a city skyline at dusk, promoting oncology research updates on BTK inhibitors and therapy in CLL.

Leukemia

12/17/2025

SEQUOIA Trial Long-Term Data Support Second-Generation BTK Inhibitors in CLL

Catherine Coombs, MDDaniel Ermann, MD

Lymphoma

View All

Bispecifics, BTK inhibitors, and immunotherapy advances in lymphoma treatment, featuring experts Dr. Rahul Gosain, Dr. Julie Vose, and Dr. Rohit Gosain at OncUpdates conference.

Lymphoma

02/26/2026

Bispecifics, BTK Inhibitors, and Immunotherapy Drive Lymphoma Advances

Julie Vose, MD, MBARahul Gosain, MD, MBARohit Gosain, MD

Lymphoma

01/15/2026

Insights on CAR-NK Therapy and Hodgkin Lymphoma Updates at ASH 2025

Sam Yamshon, MDAndrew Evens, DO, MBA, MSc

1. Expert oncologists Kingsley Nnawuba and Urshila Durani discuss advancements in lymphoma treatment, including ESMO guidelines, immunotherapy, and combination therapies for improved patient outcomes.

Lymphoma

01/13/2026

Oncologists Review Practice-Changing Lymphoma Findings From ASH 2025

Kingsley Nnawuba, MDUrshila Durani, MD, MPH

1. Experienced medical professionals discussing Sonrotoclax in mantle cell lymphoma at ASH 2025 clinical conference.

Lymphoma

12/20/2025

Experts Discuss Sonrotoclax and Lymphoma Trials at ASH 2025

Agrima Mian, MDSam Yamshon, MD

Imaging for oncological research on follicular lymphoma, featuring MDs Urshila Durani and Joshua Brody, highlighting practice-changing data from EPCORE FL-1 clinical trial in a skyline cityscape background.

Lymphoma

12/17/2025

Primary Results From EPCORE FL-1 Presented at ASH 2025

Urshila Durani, MD, MPHJoshua Brody, MD

Multiple Myeloma

View All

A groundbreaking presentation on AQUILA, COBRA, TecLLE, and MajesTEC-3 trials highlighting innovative signal shifts in myeloma management by leading oncology experts.

Multiple Myeloma

02/24/2026

AQUILA, COBRA, TecLILLE, and MajesTEC-3 Trials Signal Shifts in Myeloma Management

Ben Derman, MDRahul Gosain, MD, MBARohit Gosain, MD

Multimodal image featuring two doctors discussing cellular therapy for multiple myeloma, with cityscape background, emphasizing oncology research, CAR T-cell therapy, bispecific antibodies, and personalized cancer care advancements.

Multiple Myeloma

01/16/2026

Collaboration is Key to Safely Transition Care in MM Following Cellular Therapy

Hamza Hashmi, MDShreyas Kalantri, MD

Prognostic criteria and role of Daratumumab in high-risk smoldering myeloma, featuring experts Jing Wang, MD and Anuja Abhyankar, MD, discussing recent advancements in multiple myeloma treatment.

Multiple Myeloma

01/08/2026

Early Intervention Strategies in High-Risk Smoldering Multiple Myeloma

Anuja V. Abhyankar, MDJing Wang, MD

$1. Researchers and clinicians discuss strategies for managing lenalidomide, CD38, and multi-refractory disease in relapsed multiple myeloma treatment at OncUpdates conference.$

Multiple Myeloma

01/04/2026

How to Select Treatment in Relapsed Multiple Myeloma

Anuja V. Abhyankar, MDS. Vincent Rajkumar, MD

Early use of bispecific antibodies and CAR T strategies in relapsed multiple myeloma, discussed by experts Hamza Hashmi, MD, and Robert Orlowski, MD, PhD, with a cityscape background.

Multiple Myeloma

01/03/2026

Bispecific Antibodies and CAR T Redefine Early-Line Treatment in Multiple Myeloma

Robert Orlowski, MD, PhDHamza Hashmi, MD

Pre-transplant functional status as a predictor of autologous myeloma transplant outcomes, featuring Rahul Gosain, MD, MBA and Sawyer Bawek, DO, with a cityscape background.

Multiple Myeloma

12/29/2025

Pretransplant Functional Status as a Predictor of Outcomes in Multiple Myeloma

Sawyer Bawek, DORahul Gosain, MD, MBA